Literature DB >> 14987380

Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.

Maria João Mascarenhas Saraiva1.   

Abstract

Transthyretin (TTR) is a transport protein for thyroid hormones and vitamin A and might have an important role in the nervous system. However, TTR can undergo a conformational change and form amyloid fibrils, in both acquired and hereditary forms of systemic amyloidosis. More than 80 TTR mutations have been associated with autosomal dominant amyloidosis, usually presenting with peripheral and autonomic neuropathy and/or cardiomyopathy. Major areas of research in TTR amyloidosis include: molecular mechanisms leading to fibril formation; mechanisms of fibril-induced cell death; modulators of phenotypic expression of the disease; and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14987380     DOI: 10.1017/S1462399402004647

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  12 in total

1.  [Systemic amyloidoses].

Authors:  S Schönland; N Blank; A V Kristen; J Beimler; T Ganten; U Hegenbart
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

2.  Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.

Authors:  Anjali A Satoskar; Yvonne Efebera; Ayesha Hasan; Sergey Brodsky; Gyongyi Nadasdy; Ahmet Dogan; Tibor Nadasdy
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

3.  Discordant results between biochemical and molecular transthyretin assays: lessons learned from a unique testing algorithm at the Mayo Clinic.

Authors:  Honey V Reddi; Brittany C Thomas; Kurt S Willkomm; Matthew J Ferber; Kandelaria M Rumilla; Kimiyo M Raymond; John F O'Brien; W Edward Highsmith
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

Review 4.  Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.

Authors:  M S Mimoto; S Refetoff
Journal:  J Endocrinol Invest       Date:  2019-07-27       Impact factor: 4.256

Review 5.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

6.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

Authors:  Simon E Kolstoe; Palma P Mangione; Vittorio Bellotti; Graham W Taylor; Glenys A Tennent; Stéphanie Deroo; Angus J Morrison; Alexander J A Cobb; Anthony Coyne; Margaret G McCammon; Timothy D Warner; Jane Mitchell; Raj Gill; Martin D Smith; Steven V Ley; Carol V Robinson; Stephen P Wood; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 7.  Proteomics in molecular diagnosis: typing of amyloidosis.

Authors:  Dorothy Loo; Peter N Mollee; Patricia Renaut; Michelle M Hill
Journal:  J Biomed Biotechnol       Date:  2011-10-29

8.  Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.

Authors:  Nelson Ferreira; Maria João Saraiva; Maria Rosário Almeida
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

9.  Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).

Authors:  Arnt V Kristen; Mathew S Maurer; Claudio Rapezzi; Rajiv Mundayat; Ole B Suhr; Thibaud Damy
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

10.  Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils.

Authors:  Ricardo H Pires; Árpád Karsai; Maria J Saraiva; Ana M Damas; Miklós S Z Kellermayer
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.